SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome reported Q2 2026 net product revenue of $218.4M (+46% YoY),…

Axsome Therapeutics, Inc. · PRESS-RELEASE filed Aug 10, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Aug 10, 2026 at 07:00 ET

Axsome reported Q2 2026 net product revenue of $218.4M (+46% YoY), beating the $221.8M consensus, but GAAP EPS of -$1.26 missed the -$0.84 consensus by 49.1%. AUVELITY Alzheimer's agitation launch data showed strong early uptake (126% NBRx increase in 65+ patients), and SG&A surged 60% to $208.1M to support the expanded sales force. The net loss widened to $51.3M (-$0.99 GAAP EPS), with no change to full-year guidance but cash runway sufficient into cash-flow positivity.

  • Q2 2026 total net product revenue $218.4M (+46% YoY) vs consensus $221.8M (+1.5% beat)
  • GAAP EPS -$1.26 vs consensus -$0.84 (-49.1% miss); GAAP diluted EPS -$0.99 from net loss $51.3M
  • AUVELITY net sales $180.3M (+51% YoY); SUNOSI $35.8M (+20%); SYMBRAVO $2.3M (+461%)
  • SG&A expense $208.1M (+60% YoY) driven by Alzheimer's agitation launch and sales force expansion

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access